8-KOther EventsExhibits & Filings

COGNIZANT TECHNOLOGY SOLUTIONS CORP 8-K Report, Corporate Update (Nov 16, 2007)

Filed November 16, 2007For Securities:CTSH

Summary

Cognizant Technology Solutions Corporation (CTSH) announced on November 16, 2007, a strategic acquisition of marketRx, Inc. for approximately $135 million in cash. marketRx is a specialized provider of analytics and software services focused on the global life sciences industry. This acquisition is expected to enhance Cognizant's capabilities and offerings within the rapidly growing healthcare and life sciences sector, signaling a move to deepen its presence and expertise in this key vertical. This transaction represents a significant investment aimed at expanding Cognizant's service portfolio and competitive positioning. Investors should view this as a move to bolster the company's data analytics and software solutions within a critical and high-potential market, potentially driving future revenue growth and market share gains in the life sciences segment.

Key Highlights

  • 1Cognizant Technology Solutions acquired marketRx, Inc. for approximately $135 million in cash.
  • 2marketRx is a leading provider of analytics and related software services for global life sciences companies.
  • 3The acquisition aims to enhance Cognizant's capabilities in the life sciences sector.
  • 4This move signifies a strategic focus on expanding services within the healthcare and life sciences vertical.
  • 5The transaction was announced on November 16, 2007, and is effective immediately.

Frequently Asked Questions

This 8-K filing was made to report the material event of Cognizant Technology Solutions Corporation's acquisition of marketRx, Inc. and to file the accompanying press release.

Cognizant acquired marketRx, Inc. for approximately $135 million in cash.

marketRx is a leading provider of analytics and related software services specifically for global life sciences companies. Acquiring marketRx allows Cognizant to significantly enhance its expertise, service offerings, and market presence within the critical and growing life sciences sector.

This filing is an 8-K reporting an event; detailed financial statements related to the acquisition will be included in subsequent SEC filings (e.g., 10-Q, 10-K) as per accounting and reporting standards.